Prospective ameliorating effect of paeoniflorin against experimentally induced benign prostatic hyperplasia of Wistar rats by interfering with NF-κB/AR signaling pathway
Abstract
Background Benign prostatic hyperplasia is reported to affect 6% of population globally. BPH is a pathologic process that describes proliferative events of prostate gland cells. The development of an alternative medications against BPH based on natural components have become a priority in human and animal therapy. Present study was aimed to evaluate the role of Paeoniflorin-a terpene glycoside against testosterone induced benign prostatic hyperplasia of Wistar rats. Methods The animals were randomly assigned in to 6 groups, each group containing 6 animals: Group I: the vehicle control group (vehicle control group), Group 2: the BPH model group (BPH), Group 3: the BPH-5 mg/kg paeoniflorin group (paeoniflorin group),Group 4: the BPH-10 mg/kg paeniflorin group (paeniflorin group), Group 5: the BPH-15 mg/kg paeniflorin group (paeniflorin group) and Group 6: BPH-1 mg/kg finasteride group. Result Paeoniflorin significantly reduced the oxidative damage by increasing the activity of anti-oxidative armory and reducing the oxidative marker. A protective role of paeoniflorin against inflammation was established in blocking of NF-κB activation along with the lowering of inflammatory markers. It also reduced hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), transforming growth factor β (TGF β1) and confirms its role as anti-angiogenic phytochemical. It increased the epithelial marker E-Cadherin, reduced the activity of mesenchymal marker vimentin and…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.